Kenneth Hillan
Director/Board Member presso SANGAMO THERAPEUTICS, INC.
Patrimonio netto: 100 108 $ in data 29/02/2024
Profilo
Kenneth J.
Hillan is on the board of Sangamo Therapeutics, Inc. and Zymeworks BC, Inc.
Dr. Hillan previously occupied the position of CEO, Director & President-R&D Division at Achaogen, Inc., Chief Therapeutics Officer at 23andMe Holding Co. and Head-Therapeutics at 23andMe, Inc. (a subsidiary of 23andMe Holding Co.), SVP & Head-Roche Product Development, Asia Pacific at Genentech, Inc. and Member of Roche Group.
Dr. Hillan received a doctorate from the University of Glasgow School of Medicine.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
01/06/2023 | 49 600 ( 0.03% ) | 57 536 $ | 29/02/2024 | |
10/07/2023 | 74 688 ( 0.02% ) | 42 572 $ | 29/02/2024 | |
ZYMEWORKS INC.
-.--% | 11/10/2023 | 0 ( -.--% ) | - $ | 29/02/2024 |
Posizioni attive di Kenneth Hillan
Società | Posizione | Inizio |
---|---|---|
SANGAMO THERAPEUTICS, INC. | Director/Board Member | 11/09/2020 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Director/Board Member | 03/02/2017 |
Precedenti posizioni note di Kenneth Hillan
Società | Posizione | Fine |
---|---|---|
ZYMEWORKS INC. | Director/Board Member | 08/02/2024 |
23ANDME HOLDING CO. | Corporate Officer/Principal | 08/08/2023 |
23andMe, Inc.
23andMe, Inc. Medical SpecialtiesHealth Technology 23andMe, Inc. provides genetic information using DNA analysis technologies and web-based interactive tools. It enables individuals to gain deeper insights into personal ancestry, genealogy, and inherited traits. The company was founded by Linda Avey, Paul L. Cusenza and Anne E. Wojcicki in 2006 and is headquartered in Sunnyvale, CA. | Corporate Officer/Principal | 01/06/2021 |
ACHAOGEN | Chief Executive Officer | 04/04/2019 |
RELYPSA INC | Director/Board Member | 01/09/2016 |
Formazione di Kenneth Hillan
University of Glasgow School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
SANGAMO THERAPEUTICS, INC. | Health Technology |
23ANDME HOLDING CO. | Health Technology |
ZYMEWORKS INC. | Health Technology |
Aziende private | 6 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Achaogen, Inc.
Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Finance |
23andMe, Inc.
23andMe, Inc. Medical SpecialtiesHealth Technology 23andMe, Inc. provides genetic information using DNA analysis technologies and web-based interactive tools. It enables individuals to gain deeper insights into personal ancestry, genealogy, and inherited traits. The company was founded by Linda Avey, Paul L. Cusenza and Anne E. Wojcicki in 2006 and is headquartered in Sunnyvale, CA. | Health Technology |
Relypsa, Inc.
Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |